CAPR ALERT: Securities Fraud Class Action Launched Against Capricor Therapeutics, Inc. – September 28, 2026 Deadline

Levi & Korsinsky, LLP announced that a securities class action has been filed against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors, with a lead plaintiff deadline of September 28, 2026. The alleged class period runs from December 17, 2025 to July 29, 2026, and the complaint claims executives misled investors about changes to the pre-specified statistical analysis plan for the company's lead candidate Deramiocel. Per the allegations, the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel BLA, creating a substantial risk the agency would find the clinical data insufficient to support approval for Duchenne muscular dystrophy.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.